Publications by authors named "A M Henney"
Article Synopsis
- SGLT2 inhibitors and GLP-1 receptor agonists are diabetes treatments that may also lower the risk of pneumonia and severe sepsis in type 2 diabetes patients.
- A study using electronic medical records analyzed the effects of these drugs versus traditional glucose-lowering therapies and found significant reductions in pneumonia and sepsis risk.
- The findings suggest that both treatments could improve overall health outcomes beyond glucose control, but more research is needed to understand their full impact.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Aim: A bidirectional relationship exists between obstructive sleep apnoea (OSA) and type 2 diabetes (T2D). We aimed to examine the cumulative impact of having both OSA and T2D on patient outcomes, relative to having either condition alone.
Materials And Methods: Using TriNetX, a global federated research network (n = 128 million), we undertook two retrospective cohort studies, using time-to-event analysis.
Background: Tirzepatide, a novel dual agonist of glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), has demonstrated greater magnitude of weight loss compared to semaglutide in a phase 3 clinical trial. However, the effect of tirzepatide on incidence of type 2 diabetes (T2D) in individuals with overweight and obesity, and the effect on major adverse cardiovascular outcomes in individuals with pre-existing T2D, remains unknown.
Methods: We performed a retrospective cohort study of anonymised electronic medical records using the TriNetX network (TriNetX LLC, Cambridge, MA, USA) a global federated database.
Article Synopsis
- The study investigates the relationship between metabolic syndrome (MetS) components and the risk of micro- and macrovascular diseases in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- It used a retrospective cohort analysis of patient records, comparing those with hepatic steatosis and MetS components to those without, looking at how increasing numbers of MetS factors affect disease risk.
- Results show that MASLD, especially with multiple MetS components, significantly increases the risk for both microvascular (like neuropathy and retinopathy) and macrovascular (like heart attacks and strokes) diseases, with specific MetS factors linked to different levels of risk.